When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Apr 2025
Last updated: 30 Mar 2023

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • long-standing and progressing symptoms
  • headaches
  • erectile dysfunction
  • soft small testicles
  • gynaecomastia
  • amenorrhoea
  • infertility
  • breast atrophy
  • loss of libido
  • hot flushes
  • diaphoresis
  • weight gain
  • fatigue
  • anorexia
  • nausea
  • vomiting
  • weakness
  • decreased visual acuity
  • bitemporal hemianopia
  • pituitary apoplexy
  • diplopia

Other diagnostic factors

  • increased central adiposity
  • reduced muscle mass
  • constipation
  • cold intolerance
  • dry skin
  • hair loss
  • poor memory
  • low mood
  • osteopenia
  • weight loss
  • nervousness
  • facial numbness
  • imbalance
  • urinary incontinence
  • recurrent sinusitis
  • bradycardia
  • seizures

Risk factors

  • multiple endocrine neoplasia type 1 (MEN-1)
  • familial isolated pituitary adenomas (FIPA)
  • Carney complex (CNC)

Diagnostic investigations

1st investigations to order

  • prolactin
  • insulin-like growth factor 1
  • luteinising hormone, follicle-stimulating hormone
  • alpha subunit of human pituitary glycoprotein hormones
  • testosterone
  • estradiol
  • thyroid-stimulating hormone, free thyroxine
  • morning cortisol
  • adrenocorticotrophic hormone (ACTH) stimulation test
  • adrenocorticotrophic hormone
  • insulin tolerance test for cortisol
  • basic metabolic panel
  • FBC
  • MRI pituitary with gadolinium enhancement
  • contrast enhanced CT pituitary

Investigations to consider

  • growth hormone stimulation test
  • lipid panel
  • Humphrey or Goldmann formal visual fields test
  • immunohistochemical staining

Treatment algorithm

Contributors

Authors

Susmeeta Tewari Sharma, MD, MBBS, MHSc

Director of Pituitary Endocrinology

MedStar Washington Hospital Center/Georgetown University Hospital

Washington

DC

Disclosures

STS declares that she has no competing interests.

Acknowledgements

Dr Susmeeta Tewari Sharma would like to gratefully acknowledge Dr Gabriel Zada, Dr John Carmichael, Dr Israel Orija and Dr Amir H. Hamrahian, previous contributors to this topic. GZ, JC, IO and AH declare that they have no competing interests.

Peer reviewers

S. Bulent Omay, MD

Assistant Professor of Neurosurgery

Yale Medical School

New Haven

CT

Disclosures

SBO declares that he has no competing interests.

Andrew James, BSc, MB BCh, MD, MRCP, FRCP

Consultant Endocrinologist

Newcastle Hospitals NHS Foundation Trust

Royal Victoria Infirmary

Newcastle

UK

Disclosures

AJ declares that he has no competing interests.

Federico Roncaroli, MD

Reader in Neuropathology and Honorary Consultant in Neuropathology

Neuropathology Unit

Department of Clinical Neuroscience

Division of Neuroscience and Mental Health

Faculty of Medicine

Imperial College

London

UK

Disclosures

FR declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017 Feb 7;317(5):516-24. Abstract

Mercado M, Melgar V, Salame L, et al. Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects. [in spa]. Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):384-95. Abstract

Aghi MK, Chen CC, Fleseriu M, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on the management of patients with nonfunctioning pituitary adenomas: executive summary. Neurosurgery. 2016 Oct;79(4):521-3.Full text  Abstract

Esposito D, Olsson DS, Ragnarsson O, et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019 Aug;22(4):422-34.Full text  Abstract

Minniti G, Flickinger J. The risk/benefit ratio of radiotherapy in pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101269. Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer